Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Filaggrin Antibody (SPM181) - Azide and BSA Free, Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP254365100UG
Description
Filaggrin Monoclonal specifically detects Filaggrin in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
Filaggrin | |
Monoclonal | |
1 mg/mL | |
Flow Cytometry 0.5 - 1 ug/million cells, Immunocytochemistry/Immunofluorescence 1 - 2 ug/ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, CyTOF-ready | |
ATOD2, epidermal filaggrin, filaggrin, Profilaggrin | |
Mouse | |
Protein A or G purified | |
RUO | |
Primary | |
Filaggrin is an intermediate filament-associated protein that aggregates keratin intermediate filaments in mammalian epidermis. It is initially synthesized as a polyprotein precursor, profilaggrin (consisting of multiple filaggrin units of 324 aa each), which is localized in keratohyalin granules, and is subsequently proteolytically processed into individual functional filaggrin molecules. Active filaggrin is present at a level of the epidermis where keratinocytes are in transition between the live nucleated granular layer and the anucleate cornified layer, suggesting that filaggrin aids in the terminal differentiation process by facilitating apoptotic machinery. | |
Store at -20 to -80C. Avoid freeze-thaw cycles. | |
IgG1 κ |
Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), CyTOF | |
SPM181 | |
Unconjugated | |
PBS with No Preservative | |
FLG | |
Recombinant human Filaggrin protein | |
100 μg | |
Cytoskeleton Markers | |
2312 | |
Human | |
Purified |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?
Provide Content Correction